dr megan carter glp 1 Gila monster venom… and weight loss? 🦎 It sounds wild, but it's true. GLP-1 medications were inspired by a hormone first discovered in the saliva of a Gila monster. On this week's New study on GLP-1 drugs

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Its dangerous, but for people like this author, the risks feel worth it.

Obviously, it is too early to be overly hopeful since it is still necessary to determine the long-term effects of these compounds and properly verify the potential cardiovascular benefits

Learn how Michigans rising obesity trends are influencing the demand for GLP-1 medications like Wegovy, Zepbound, and Mounjaro.

In addition, the effect of l-valine on hormone secretion from the distal intestine was investigated using a perfused rat colon

Weight-loss pens have been available on the pharmaceutical market for about a decade, initially appearing internationally